Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...

Povorcitinib is an oral Janus kinase 1 selective inhibitor that works to reduce the overactive inflammatory signaling pathway seen in HS.

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

As previously reported, Guggenheim downgraded Incyte (INCY) to Neutral from Buy and removed the firm’s previous $92 price target after the ...

Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...

Shares of Incyte INCY were down 8.62% on Monday after the announcement of data from two late-stage studies on an oral ...

Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients with Hidradenitis ...

Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...

The Wilmington, Del., biopharmaceutical company said the study data support planned worldwide regulatory submissions for povorcitinib for the treatment of hidradenitis suppurativa, which can lead to ...

Read about Alcidion, Sarepta Therapeutics and more in the latest Market Talks covering the Health Care sector.

Incyte (INCY) announced topline results from its Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib, an ...

Omeros Corporation OMER shares dipped 4.4% to $8.05 in pre-market trading after gaining 7% on Friday. Neogen Corporation NEOG ...